Siena, Italy

Claudio Donati

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Claudio Donati. Retrieved from https://idiyas.com/inventor/claudio-donati-kh2vu2di

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Claudio Donati: Innovator in Adjuvant Research

Introduction

Claudio Donati is a notable inventor based in Siena, Italy. He has made significant contributions to the field of immunology through his innovative research and development of adjuvant compositions.

Latest Patents

Donati holds a patent for "Pamps, pathogen associated molecular patterns - A method for identifying a polypeptide which acts as an adjuvant in a host organism." This invention provides a method for identifying polypeptides that enhance the immune response, along with adjuvant compositions that may include these polypeptides and additional antigens.

Career Highlights

Claudio Donati is currently associated with Novartis AG, a leading global healthcare company. His work focuses on advancing the understanding of immune responses and developing new therapeutic strategies.

Collaborations

He has collaborated with esteemed colleagues such as Jeffrey Ulmer and Nicholas M Valiante, contributing to the advancement of research in his field.

Conclusion

Claudio Donati's innovative work in adjuvant research exemplifies the importance of scientific inquiry in enhancing immune responses. His contributions continue to influence the field of immunology and therapeutic development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…